2006
A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care
Sullivan LE, Barry D, Moore BA, Chawarski MC, Tetrault JM, Pantalon MV, O'Connor PG, Schottenfeld RS, Fiellin DA. A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care. Clinical Infectious Diseases 2006, 43: s184-s190. PMID: 17109305, DOI: 10.1086/508182.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, SublingualAdultAntiretroviral Therapy, Highly ActiveBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansMaleMiddle AgedNaloxoneNarcotic AntagonistsOpioid-Related DisordersPilot ProjectsProbabilityReference ValuesRisk FactorsTreatment OutcomeConceptsHIV clinical careHIV-1 RNA copies/mLBuprenorphine/naloxone treatmentRNA copies/mLCopies/mLOpioid dependenceClinical careOpioid useNaloxone treatmentPhysician managementTreatment retentionHIV type 1 RNA levelsHIV-1 RNA levelsDose of buprenorphinePartial opioid agonistRNA levelsCD4 lymphocyte countBuprenorphine/naloxoneOpioid-dependent patientsUrine toxicology testsWeeks of treatmentHuman immunodeficiency virusUrine test resultsBetter treatment retentionUntreated opioid dependence
2005
Response to hepatitis A vaccine in HIV‐positive patients1
Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV‐positive patients1. Journal Of Viral Hepatitis 2005, 13: 81-86. PMID: 16436125, DOI: 10.1111/j.1365-2893.2005.00658.x.Peer-Reviewed Original ResearchConceptsHepatitis A virusHigher CD4 countsHuman immunodeficiency virusCD4 countHAV vaccineVaccine administrationFemale genderImmune responseMultivariate analysisHepatitis C virus exposureUSPHS/IDSA guidelinesHIV-negative patientsAntiretroviral therapy useChronic liver diseasePredictors of responseLow viral loadIDSA guidelinesVaccination seriesHIV patientsIndependent predictorsTherapy useLiver diseaseOpportunistic infectionsViral loadImmunodeficiency virus